rituximab


Also found in: Medical, Wikipedia.

ri·tux·i·mab

 (rĭ-tŭk′sĭ-măb′)
n.
A chimeric monoclonal antibody used to treat certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and refractory rheumatoid arthritis.

[ri-, origin unknown + tu(mor) + -xi- (alteration of chi(meric), influenced by X, Greek letter chi) + m(onoclonal) a(nti)b(ody).]

rituximab

(rɪˈtʌksɪˌmæb)
n
a monoclonal antibody used to treat non-Hodgkin's lymphoma
Translations

rituximab

n rituximab m
Mentioned in ?
References in periodicals archive ?
The ongoing Phase II/III in PPMS will test the effect of rituximab versus placebo in 450 patients for a total of 2 years of therapy (four courses).
Trial results have shown that maintenance treatment with rituximab can almost halve the risk of death for patients with follicular non-Hodgkin lymphoma (NHL).
The anticancer drug rituximab thwarts inflammatory nerve damage in the brain and curbs relapses in people with multiple sclerosis (MS), a study suggests.
After years of case reports and small series, three publications this year now provide us with timely data demonstrating the safety and efficacy of an anti-CD20 monoclonal antibody, rituximab, in patients with HIV-associated MCD.
Emmanuelle Waubant is one of a team of investigators at the University of California San Francisco MS Center collaborating in multicenter trials of rituximab (Rituxan).
After completion of the rituximab therapy, the factor XIII activity was 58% with no inhibitor present.
VIENNA -- B-cell depletion with rituximab led to significant improvements in patients with CNS neuropsychiatric disability associated with systemic lupus erythematosus, according to a preliminary report presented by C.
Infusion-related toxicities were typically grade 1 or 2 and were associated with pre-administration of Rituximab (RITUXAN).
More recently, the AMC trial 010 was unable to show that HIV-positive people benefited from the addition of Rituximab (a monoclonal antibody that attacks cancerous lymphoma cells) to a standard chemotherapy regimen.
In trials, the drug, rituximab, was so effective on some patients they were able to return to work and even go to the gym for the first time after 20 years.
The drug, rituximab, acts by suppressing antibody production within the immune system and breaking a key part of the cycle that leads to arthritic inflammation.